GAIN THERAPEUTICS, INC Current Income Tax Expense (Benefit)
GAIN THERAPEUTICS, INC (GANX) reported Current Income Tax Expense (Benefit) of $861.12 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-26
- GAIN THERAPEUTICS, INC current income tax expense (benefit) for fiscal 2025 was $861.12K, a 60.41% increase from fiscal 2024.
- GAIN THERAPEUTICS, INC current income tax expense (benefit) for fiscal 2024 was $536.82K, a 577.16% increase from fiscal 2023.
- GAIN THERAPEUTICS, INC current income tax expense (benefit) for fiscal 2023 was $79.28K, a 14.74% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC current income tax expense (benefit) for fiscal 2022 was $92.98K, a 2219.76% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $861.12K 10-K · filed 2026-03-26 |
| 2024-12-31 | $536.82K 10-K · filed 2026-03-26 |
| 2023-12-31 | $79.28K 10-K · filed 2025-03-27 |
| 2022-12-31 | $92.98K 10-K · filed 2024-03-26 |
| 2021-12-31 | $4.01K 10-K · filed 2023-03-23 |
| 2020-12-31 | $5.39K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |